Literature DB >> 8188703

Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence.

T Wakita1, J R Wands.   

Abstract

The effect of sense and antisense oligodeoxynucleotides (ODNs) on hepatitis C virus (HCV) gene expression was studied to determine the role of the highly conserved 5'-untranslated region in the life cycle of the virus. It was found that antisense ODNs complementary to nucleotides (nt) 38-65, 134-175, and 312-339 in the 5' noncoding region and 341-377 in the core open reading frame efficiently blocked HCV RNA translation. Overlapping ODNs that differed by only several nucleotides showed substantially different inhibition of HCV RNA translation. Fine sequence specificity testing at nt positions 351-377 revealed that ODNs as small as a 12-mer (nt 351-363) retained a high degree (80%) of inhibitory activity compared to ODNs of longer sequences. These results suggest that there are three highly specific domains in the 5' noncoding region and a sequence immediately downstream of the HCV core initiation codon that may be critical for translation of HCV RNA. This study also provides an experimental approach for the selection of target HCV RNA sequences susceptible to antisense effects, as well as for definition of functional regions of the genome necessary for viral replication.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188703

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Inhibition of hepatitis B virus X gene expression by novel DNA enzymes.

Authors:  R Goila; A C Banerjea
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

2.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Authors:  E A Biessen; H Vietsch; E T Rump; K Fluiter; J Kuiper; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

Review 3.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

4.  Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes.

Authors:  R Hanecak; V Brown-Driver; M C Fox; R F Azad; S Furusako; C Nozaki; C Ford; H Sasmor; K P Anderson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Plant ribosome shunting in vitro.

Authors:  W Schmidt-Puchta; D Dominguez; D Lewetag; T Hohn
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

Review 6.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside Triphosphatase/Helicase domain of the hepatitis C virus nonstructural 3 protein.

Authors:  Z X Zhang; U Lazdina; M Chen; D L Peterson; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

8.  Specific interaction of a 25-kilodalton cellular protein, a 40S ribosomal subunit protein, with the internal ribosome entry site of hepatitis C virus genome.

Authors:  S Fukushi; M Okada; T Kageyama; F B Hoshino; K Katayama
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

9.  The native form and maturation process of hepatitis C virus core protein.

Authors:  K Yasui; T Wakita; K Tsukiyama-Kohara; S I Funahashi; M Ichikawa; T Kajita; D Moradpour; J R Wands; M Kohara
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.